By API User
Sydney, Australia – 12 March 2025 | BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) is pleased to announce that the first patient has been tested in its pivotal U.S. autism diagnostic study, marking the official commencement of the largest digital diagnostic trial for autism in the United States. The trial is designed to validate BlinkLab … Continued
By API User
11 March 2025 – Sydney, Australia | ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce key milestones in its Asian market expansion, including marketing approval for the NervAlign® Nerve Cuff™ in Thailand, as well as its first hospital stocking order in Hong Kong. These developments strengthen ReNerve’s commercial presence outside the initial … Continued
By API User
ZUG, SWITZERLAND AND VILNIUS, LITHUANIA / ACCESS Newswire / March 4, 2025 / Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable … Continued
By API User
LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that its Chief Scientific and Clinical Advisor, Professor Eric Chung, will present pivotal SPONTAN® clinical trial data at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting in Perth, from 1 to 4 March 2025. Highlights 470% Faster Absorption: … Continued
By API User
ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce it has signed an exclusive distribution partnership agreement with Imbiomex, a leading Mexican medical device distribution company, in order to progress the NervAlign® Nerve Cuff through regulatory approval and commercial distribution in Mexico. Highlights ReNerve partners with Imbiomex to secure regulatory approval and launch … Continued
By API User
Highlights: • BTC statutory profit after tax of $4.9m (1H FY24: $1.7m) • BTC and investee companies consolidated 1H FY25 performance: • revenue up 9% to $5.3m (1H FY24: $4.9m) • gross profit up 6% to $2.3m (1H FY24: $2.2m) • operating expenses remain well controlled at $2.1m (1H FY24: $2.1m) • EBITDA of $0.2m (1H FY24: … Continued
By API User
Highlights: • Optiscan reveals InForm™, its next generation microscopic medical imaging device specifically designed for pathology workflows. • InForm™ expands Optiscan’s product portfolio into the pathology market, marking a pivotal milestone in advancing the Company’s strategic objectives. • InForm™ can be used in a variety of pathology settings, most notably in laboratory medicine, pathology practice, point-of-care and … Continued
By API User
Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together. Surgeons routinely use stainless steel or titanium, which stay in the body forever, can cause discomfort and may require follow-up surgeries. A … Continued
By API User
Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment of Salesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025. This appointment reflects the underlying expansion of the BTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from … Continued
By API User
• License and distribution agreement for Bronchitol and Aridol converted from an initial 10- year term to an indefinite license • BTC to earn royalties from sales of Bronchitol and Aridol in Singapore and Malaysia • BTC granted first right of refusal to Arna Pharma’s new product pipeline Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the … Continued
